http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Computational Study on the Rotordynamic of the Hole Diaphragm Labyrinth Seal
Xiang Zhang,Yinghou Jiao,Xiuquan Qu,Guanghe Huo 제어로봇시스템학회 2022 제어로봇시스템학회 국제학술대회 논문집 Vol.2022 No.11
The seal structure is an efficient way to reduce leakage and improve rotor stability in gas turbine machines. Various seals have been proposed to achieve this goal in the last century. Labyrinth seals (LS), one of those seals, are widely used in industry due to their relatively simple structure. This paper studied whirl radius dependence of hole diaphragm labyrinth seal (HDLS), which designed by adding hole-diaphragms in LS. A series of working conditions of whirl frequencies, rotation speeds and whirl radius rates were considered in simulations. The characteristic parameters in the rotordynamic model of the seal rotor system were calculated. The results show that a better stiffness performance of HDLS was obtained than those of LS and diaphragm labyrinth seal (DLS) on the small whirl radius. The effective damping of HDLS is slightly better than that of LS but moderately worse than that of DLS at higher rotation speeds. The adaptability under multiple working conditions of HDLS represents its feasibility, which can be used in seal-rotor systems. The analysis of the new type of labyrinth seal proposed in this paper confirmed some advantages in gas turbine and steam turbine applications and is worthy of further study.
Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis
Hongyan Cheng,Lanqing Huo,Dan Wang,Yang Xiang 대한부인종양학회 2019 Journal of Gynecologic Oncology Vol.30 No.6
Objective: To analyze the clinical characteristics, prognosis and parallel clinical course ofovarian cancer (OC) and dermatomyositis (DM). Methods: The medical records of 23 consecutive patients who were diagnosed with OC andDM and were treated at Peking Union Medical College Hospital (PUMCH) between 2002and 2017 were reviewed. Propensity score matching method was used to match controlgroup (OC patients without DM) at a ratio of 1:5. The correlation between OC and DM wasmeasured using the Pearson correlation scatter plot and Pearson's r. Kaplan-Meier survivalanalysis and Cox proportional hazard regression analysis were performed to evaluate theprognostic factors. Results: After matching, 23 patients who have the concurrence of OC and DM (DM group)and 115 patients diagnosed with OC alone (No DM group) were included. The 5-year overallsurvival rates (71.6% vs. 51.8%, p=0.020) and 5-year progression-free survival (30.5% vs. 0%, p=0.018) were poorer in DM group. Correlation between serum cancer antigen 125 (CA125) and creatine kinase (CK) level was observed in 12 patients. The time between OC andDM diagnosis is significant through univariable analysis (p=0.021) but not in multivariableanalysis in patients who have the concurrence of OC and DM. Conclusion: The concurrence of OC and DM as a paraneoplastic syndrome is rare and has apoor prognosis. The risk for patients diagnosed with DM is highest within 3 years before orafter OC diagnosis. A correlation and a parallel clinical course exist between these 2 diseases.
Jia Hu,Li Liu,Xiang Chen,Ping Chen,Guang-li Yang,Wen-li Hou,Ming-hai Tang,Fan Zhang,Xian-huo Wang,Xia Zhao,Yu-quan Wei,Li-juan Chen 생화학분자생물학회 2008 Experimental and molecular medicine Vol.40 No.6
Honokiol is an active compound purified from magnolia that has been shown to induce cell differentiation, apoptosis, and anti-angiogenesis effects, as well as an enhancement in tumor growth delay in combination with chemotherapeutic agents in several mouse xenograft models. Our goal was to investigate the radiosensitization effect of honokiol on lung carcinoma. The radiosensitization effect of liposomal honokiol in Lewis lung carcinoma cells (LL/2) was analyzed using an in vitro clonogenic survival assay. For an in vivo study, Lewis lung carcinoma-bearing C57BL/6 mice were treated with either liposomal honokiol at 25 mg/kg or 5 Gy of single tumor radiation, or a combination of both over 12 days of treatment. The tumor growth delay and the survival time were evaluated. In addition, histological analysis of tumor sections was performed to examine changes by detecting the microvessel density and apoptosis in tumor tissues. In the clonogenic survival assay, LL/2 cells treated with IC50 Lipo-HNK for 24 h showed a radiation enhancement ratio of 1.9. After 12 days of combination treatment, the tumor volume decreased 78% and produced an anti-tumor activity 1.3-fold greater than a predicted additive effect of honokiol and radiation alone. This combination treatment also caused an 8.7 day delay in tumor growth. The cell cycle distribution and histological analysis demonstrated that liposomal honokiol has an anti-tumor effect via inducing apoptosis and inhibiting angiogenesis. Liposomal honokiol can enhance tumor cell radiosensitivity in vitro and in vivo, indicating that radiotherapy combined with liposomal honokiol can lead to greater anti-tumor efficacy. Honokiol is an active compound purified from magnolia that has been shown to induce cell differentiation, apoptosis, and anti-angiogenesis effects, as well as an enhancement in tumor growth delay in combination with chemotherapeutic agents in several mouse xenograft models. Our goal was to investigate the radiosensitization effect of honokiol on lung carcinoma. The radiosensitization effect of liposomal honokiol in Lewis lung carcinoma cells (LL/2) was analyzed using an in vitro clonogenic survival assay. For an in vivo study, Lewis lung carcinoma-bearing C57BL/6 mice were treated with either liposomal honokiol at 25 mg/kg or 5 Gy of single tumor radiation, or a combination of both over 12 days of treatment. The tumor growth delay and the survival time were evaluated. In addition, histological analysis of tumor sections was performed to examine changes by detecting the microvessel density and apoptosis in tumor tissues. In the clonogenic survival assay, LL/2 cells treated with IC50 Lipo-HNK for 24 h showed a radiation enhancement ratio of 1.9. After 12 days of combination treatment, the tumor volume decreased 78% and produced an anti-tumor activity 1.3-fold greater than a predicted additive effect of honokiol and radiation alone. This combination treatment also caused an 8.7 day delay in tumor growth. The cell cycle distribution and histological analysis demonstrated that liposomal honokiol has an anti-tumor effect via inducing apoptosis and inhibiting angiogenesis. Liposomal honokiol can enhance tumor cell radiosensitivity in vitro and in vivo, indicating that radiotherapy combined with liposomal honokiol can lead to greater anti-tumor efficacy.
Huang, Xin-En,Wei, Guo-Li,Huo, Jie-Ge,Wang, Xiao-Ning,Lu, Yan-Yan,Wu, Xue-Yan,Liu, Jin,Xiang, Jin,Feng, Ji-Feng Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.4
Aims: To explore efficacy and side effects of intrapleural or intraperitoneal lobaplatin for treating patients with malignant pleural or peritoneal effusions. Methods: Patients in Jiangsu Cancer Hospital and Research Institute with cytologically confirmed solid tumors complicated with malignant pleural effusion or ascites were enrolled into this study. Lobaplatin (20-30 $mg/m^2$) was intrapleurally or intraperitoneally infused for patients with malignant pleural effusion or ascites. Results: From 2012 to 2013, intrapleural or intraperitonea lobaplatin was administered for patients with colorectal or uterus cancer who were previous treated for malignant pleural effusion or ascites. Partial response was achieved for them. Main side effects were nausea/vomiting, and bone marrow suppression. No treatment related deaths occurred. Conclusion: Intrapleural or intraperitoneal infusion of lobaplatin is a safe treatment for patients with malignant pleural effusion or ascites, and the treatment efficacy is encouraging.